Associate Professor, Director of Genitourinary Clinical Research, Fox Chase Cancer Center
Oncology
Dr. Elizabeth R. Plimack, MD
|
|
Give Review
Elizabeth Plimack is an expert in the field of Oncology. He graduated from NYU School of Medicine. He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Whos Who in Medicine and Healthcare". Elizabeth Plimack has written publications. He has 29 publications published with PubMed. The lastest paper is: 'Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care.' Elizabeth Plimack accepts Medicare.
Publications
- Advanced small cell carcinoma of the Bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma.
- Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care.
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer.
- Kidney Cancer, version 3.2015.
- Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell Carcinoma: a review of clinical trials.
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
- Evaluating toxicity from definitive radiation therapy for prostate Cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with mode...
- Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors.
- Micropapillary bladder Cancer: Current treatment patterns and review of the literature.
- A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection.
- Coexisting hybrid malignancy in a solitary sporadic solid benign Renal mass: implications for treating patients following Renal biopsy.
- Kidney Cancer, version 2.2014.
- Prostate Cancer, version 1.2014.
- Lymphopenia is an Independent Predictor of Inferior Outcome in Clear Cell Renal Carcinoma.
- Prolonged natural progression from localized to symptomatic renal cell Carcinoma.
- Selecting targeted therapies for patients with renal cell Carcinoma.
- Clinical stage t1 micropapillary urothelial Carcinoma presenting with metastasis to the pancreas.
- NCCN clinical practice guidelines in oncology: prostate Cancer.
- Patterns of disease progression in metastatic renal cell Carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns a...
- Combining epigenetic and cytotoxic therapy in the treatment of solid Tumors.
- Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian Carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern C...
- A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell Carcinoma and soft tissue sarcoma.
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors.
- Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder Cancer and is minimally affected by radical cystec...
- Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial Carcinoma: further evidence to support the use of neoadjuvant chemotherapy.
- Decitabine and its role in the treatment of hematopoietic Malignancies.
- Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian Cancer: an NYGOG and ECOG study.
Schools
New York University
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Geisinger Health Plan
- Community Blue PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- MagnaCare
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Whos Who in Medicine and Healthcare
Education
-
University of Texas Health Science Center -
NYU School of Medicine
Hospital
-
Fox Chase Cancer Center-American Oncologic Hospital
Drug Facts
| NPI NUMBER | 1477647659 | |
| NPPES Provider LastName | PLIMACK | |
| NPPES Provider FirstName | ELIZABETH | |
| NPPES Provider ZIPCode | 19111 | |
| NPPES Provider State | PA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 606.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 42.0 | |
| Percent Opioid Claims | 6.93 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477647659 |
| Last Name Of The Provider | PLIMACK |
| First Name Of The Provider | ELIZABETH |
| View All |
Similar Doctors
|
|
Dr. Gary R. Hudes, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Juhi Mittal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shayma M. Kazmi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory L. Beatty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vikram R. Paralkar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Deric C. Savior, MD
This Doctor is OpenDoctor Recommended.
|